Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1
- Registration Number
- NCT01586052
- Lead Sponsor
- MinYoung Kim, M.D.
- Brief Summary
This purpose of this phase 1 study is to investigate the safety and efficacy of erythropoetin for children with cerebral palsy.
- Detailed Description
Cerebral palsy is a disorder of movement and posture resulted from a nonprogressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability.
Many experimental animal studies have revealed that erythropoietin is useful to repair neurological injury in brain. The main mechanism of erythropoietin is supposed as follows; neuroprotection effect, angiogenesis, and anti-inflammation.
On the basis of many experimental studies, erythropoietin is suggested as a potential therapy for cerebral palsy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
- Cerebral Palsy
- Abnormal Muscle Tone
- GMFCS (Gross Motor Functional Classification System): II to IV
- Age: 6 months ~ 3 years
- Abnormal Brain MRI compatible to clinical features and non-progressive
- Willing to Comply with All Study Procedure
- Known Genetic Disorder
- Baseline Erythropoietin level > 45 mU/mL
- Presence of Drug Hypersensitivity Related to the Study Remedy
- Previous Erythropoietin Treatment before 3 months
- Coagulopathy:
Family History, Unknown Cerebral Infarction, Thromboembolic Events History
- Intractable Seizure Disorder
- Poor Cooperation of Guardian including Inactive Attitude for Rehabilitation
- Uncontrolled Hypertension
- Liver Dysfunction
- Renal Dysfunction
- Absolute Neutrophil Count < 500/dL
- Intracerebral or Intraventricular Hemorrhage
- Malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Erythropoietin and Rehabilitation Erythropoietin recombinant human erythropoietin injection and active rehabilitation
- Primary Outcome Measures
Name Time Method Adverse Events 8 weeks Monitoring of all adverse events during 8 weeks, the study period We selected specially considered adverse events: encephalopathy, intracranial hemorrhage, seizure, hypertension, thromboembolic event, hypoxia, and acute kidney injury. Other adverse events will be recorded. The list was determined by the clinical experience and all adverse reactions reported by the pharmaceutical company.
- Secondary Outcome Measures
Name Time Method Changes in Quality of Movement Baseline - 8 weeks GMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones: alignment, coordination, dissociated movement, stability, and weight shift The interrater reliability of GMPM subscores and total scores was 0.758-0.886 (subject n=75, tester n=10).
Changes in Gross Motor Function Baseline - 8 weeks GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of 6 sub-scales; lying \& rolling, sitting, crawling \& kneeling, standing, walking, running \& jumping The measured interrater reliability of GMFM subscores and total scores was 0.974 - 0.997 (subject n=101, tester n=10) and intrarater reliability of GMFM subscores and total scores between one most experienced rater and another newly t rained rater was 0.994 - 1.000 (subject n=101, tester n=2).
Changes in Neurodevelopmental Outcomes Baseline - 8 weeks K-BSID-II (Korean version of Bayley Scale of Infant Development-II) Motor and Mental scales The measured intrarater and interrater reliability of K-BSID-II motor and mental scales was 0.92 - 0.99 (subject n=55, tester n=10).
Changes in Motor Development Baseline - 8 weeks AIMS (Alberta Infant Motor Scale) to assess motor development
Changes in Spasticity Baseline - 8 weeks MAS (modified Ashworth Scale) measured at biceps, hip adductor, hamstring, heel cord
Trial Locations
- Locations (1)
CHA Bundang Medical Center, CHA University
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of